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Abstract
Background: Tuberculous meningitis is the most severe manifestation of extrapulmonary tuberculosis with a high
mortality rate and a high rate of sequelae among survivors. The aim of this study is to assess the current
epidemiology, clinical features, diagnostic procedures, treatment and outcome in patients with tuberculous
meningitis in Denmark, a country with a low tuberculosis incidence.
Methods: A nationwide retrospective study was conducted, comprising all patients notified with tuberculous
meningitis (TBM) in Denmark from 2000-2008. Medical records were reviewed using a standardised protocol.
Results: Fifty patients, including 12 paediatric patients, were identified. 78% of the patients were immigrants from
countries of high tuberculosis endemicity. 64% of all patients had a pre-existing immunosuppressive condition;
10% were HIV positive, 48% were HIV seronegative and 42% had an unknown HIV status. Median symptom
duration before admission was 14 days in the Danish patient population and 20 days in the immigrant group.
Biochemical analysis of cerebrospinal fluid (CSF) samples revealed pleocytosis in 90% with lymphocyte
predominance in 66%. Protein levels were elevated in 86%. The most common findings on neuro-radiological
imaging were basal meningeal enhancement, tuberculomas and hydrocephalus. Lumbar puncture was performed
on 42 patients; 31 of these specimens (74%) had a positive CSF culture for mycobacteria and 9.5% were smear
positive for acid-fast bacilli. The overall mortality rate was 19% and 48% of the remaining patients had neurological
sequelae of varying degree.
Conclusion: TBM is a rare but severe manifestation of extrapulmonary TB in Denmark. The clinician must be
prepared to treat empirically if the suspicion of TBM has arisen to improve treatment outcome.
Background
Tuberculosis (TB) of the central nervous system is the
most severe manifestation of extrapulmonary TB and
constitutes approximately 1% of all new cases annually
[1]. Although the incidence of tuberculous meningitis
(TBM) is low in high-income countries, it remains one
of the most severe and eventually fatal infectious condi-
tions - especially in times of increasing use of immuno-
suppressive drugs, increased access to transplantation
(also for patients from TB endemic countries), changing
HIV patterns and increasing prevalence of type II
diabetes.
TBM is characterised by a slowly progressing granulo-
matous inflammation of the basal meninges. This
inflammatory reaction can lead to a number of compli-
cations, such as hydrocephalus, cerebral vascular infarc-
tion, cranial nerve palsy and, if left untreated, death.
Rapid diagnosis and initiation of treatment is therefore
necessary to reduce the high mortality and severe seque-
lae associated with the disease. Diagnosing TBM can be
difficult as the symptoms are unspecific and mimic
those of meningitis caused by other microbiological
agents or other cerebrovascular events.
Denmark has a low TB incidence of 6.7/100.000 with
367 notified cases in 2008 [2]; yet, the country has had
fluctuations in the annually reported number of TB cases
throughout the last 20 years. In 1986 there was an all-time
low of 299 new cases [3] and in 2000 there was a peak
of 548 new cases [4], equalling an increase of 83% in
14 years. This increase was primarily due to an increase in
immigration from high-incidence countries [3,5].
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Methods
To initiate this retrospective study we obtained data on
notified TBM cases from the National TB Notification
Register between January 2000 and December 2008. The
medical records of all patients, including children, with
TBM were retrieved from Paediatric Departments and
Departments of Infectious Diseases at five major Univer-
sity Hospitals in Denmark. Of note, in Denmark all
cases of tuberculous meningitis are treated at university
hospitals as required by national guidelines. Permission
was granted from the Danish Data Protection Agency.
Demographic data, medical history, clinical presenta-
tion at admission, radiological and microbiological data
was reviewed along with the clinical course, treatment
and outcome. All microbiological data was retrieved
from The International Reference Laboratory of Myco-
bacteriology at Statens Serum Institut.
Results
Demography
50 cases of cerebral TB were notified throughout the per-
iod; out of these 15 (30%) had tuberculomas. A total of
12 paediatric patients (aged 1-15 years) were found. All
results have been divided into two sub-groups - one con-
sisting of native Danish patients, the other of immigrants.
The immigrant group of patients in this study includes
patients born abroad and their children up to 25 years of
age, as well as people from Greenland living in Denmark.
A total of 11 patients (22%) were native Danes, the
remaining 39 (78%) were immigrants from varying coun-
tries; three from Greenland, three from Ex-Yugoslavia,
four from Sub-Saharan African countries with high HIV
prevalence (Ethiopia, Uganda, South Africa), 22 from
the Eastern Mediterranean region as defined by the
World Health Organisation, WHO, (primarily Morocco,
Somalia, Pakistan), and seven from Asia (China, India,
Indonesia, Vietnam, Cambodia). 13 out of the 15 (87%)
tuberculoma patients were immigrants.
There was an equal sex distribution in the two groups.
Median age for the Danish patients was 17 years (range
1-52) and for the immigrant group 34 years (range 1-71).
Further demographic data are specified in Table 1.
Six Danish patients (55%) had pre-existing immuno-
suppressive diseases or conditions like malignancy or
diabetes. Three patients were taking immunosuppressive
medication due to organ transplant. Some were
recorded as having a drug and/or alcohol abuse, and
one patient was known HIV positive at the time of
TBM diagnosis.
Similar results were found in the immigrant group
with 26 out of 39 patients (67%) having one or more
dispositions. Among these patients, four were HIV posi-
tive, two had kidney transplants, six had diabetes and
four were recorded as having an alcohol abuse. Two
patients had a family member who had recently been
treated for TB.
Within the two patient populations, a total of 24 patients
(48%) were HIV seronegative and 21 had an unknown
HIV status (42%).
Clinical presentation
Over half the patients presented with fever and head-
ache. The classic sign of meningeal stiffness was found
in less than half the patients. Neurological signs upon
admission was affected in the majority of cases: 52% of
the patients were described with a general altered men-
tal state (i.e. confusion), 36% had cranial nerve paralysis
(predominantly facial nerve or abducens nerve affection)
and 16% presented with generalised convulsions upon
hospitalization (Table 1).
Five of the immigrant patients were initially admitted
at neurology departments with headaches, convulsions
and altered cerebral conditions. Due to symptoms of
Table 1 Demographic data, clinical presentation and
outcome
Danes
(n = 11)
Immigrants
(n = 39)
Male sex (%) 6 (54) 18 (46)
Age, median (range), years 17 (1-52) 34 (1-71)
Pre-existing diseases or conditions (%) 6 (54) 26 (67)
HIV infected patients (%) 1 (9) 4 (10)
Symptom duration, median (range), days 14 (3-180) 20 (5-180)
General symptoms & signs
Fever (%) 11 (100) 31 (79)
Headache (%) 5 (45) 31 (79)
Meningeal stiffness (%) 2 (18) 19 (49)
Weightloss (%) 4 (36) 14 (36)
Neurological symptoms
Confusion (%) 6 (54) 20 (51)
Cranial nerve paralysis (%) 4 (36) 14 (36)
Convulsions (%) 1 (9) 7 (18)
Extra-cerebral TB manifestations
Pulmonary TB (%) 6 (54) 17 (44)
Other localizations (%) 1 (9) 9 (23)
Delay in treatment, median (range), days 7 (0-30) 3-4 (0-52)
Outcome*
Full recovery (%) 2 (18) 14 (38)
Sequelae (%) 6 (54) 17 (46)
Death (%) 3 (27) 6 (16)
*n = 37 in the immigrant group as two patients were lost for follow-up.
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increased intra-cranial pressure, these patients under-
went CT scanning and tumour like processes were iden-
tified. A lumbar puncture was never performed on any
of these patients. They were transferred to neurosurgery
departments for brain biopsy. Diagnosis was achieved
based on histology and culture results.
Symptom duration before admission ranged greatly
with a median of 14 days in the Danish patients and
20 days in the immigrant group.
The tuberculin skin test was not performed routinely
in all patients; only 20 results were available for this
study; 15 (75%) were positive. BCG scar status had not
been noted in any of the reviewed patient files.
Cerebrospinal fluid characteristics
A total of 42 patients had a lumbar puncture performed at
the time of admission. The remaining eight patients all had
tuberculomas and did not have lumbar puncture per-
formed due to symptoms of increased intra-cranial pres-
sure. The white cell count (WCC) was elevated in 38
patients (90%) with lymphocyte predominance in 66%. Pro-
tein levels were elevated in 36 patients (86%). Eleven
patients had a protein level above 3 g/L. The glucose con-
tent was below the minimum reference value in 20 patients
(48%). CSF:blood glucose ratios could be calculated in a
total of 26 patients; this ranged from 0,09 - 0,71. The ratio
was below 0,3 in 50% of these patients (Table 2). Eight out
of the nine fatal cases had pleocytosis and elevated protein
levels. Only one of the fatal cases had a normal WCC but
the CSF had elevated protein content; diagnosis was in this
case established by a positive CSF culture.
Radiology
All patients were investigated with either cranial CT or
MR scans at time of admission; 22 patients had both
scans performed (Table 3). Cranial MR scans showed
basal meningeal enhancement in six Danish patients and
in 10 immigrants. Tuberculomas were more frequently
found in the immigrant patient group. Eight patients
with normal CT scans went on to have a cranial MR
scan performed and this contributed diagnostically in
showing basal meningeal enhancement in all. Eight
patients had the combined finding of hydrocephalus and
fresh infarct on both CT and MR scans. Only one
patient presented both a normal CT and MR scan.
Chest X-rays were performed in 48 patients and was
found abnormal in 26 cases (54%). Concomitant pul-
monary TB was microbiologically verified in 23 cases.
Microbiology
Results from microbiological analyses performed on CSF
are shown in Table 2. In 41 patients (82%) the diagnosis
was verified by culture. The number of days before
31 CSF cultures became positive ranged between 7 to
46 days (median 20 days). Nucleic acid amplification
(NAA) test was positive for M. tuberculosis complex in
one sample, but the culture remained negative. In five
cases, microbiological diagnosis was obtained through
cultures of biopsies from tuberculomas. Furthermore,
five patients had positive cultures of non-cerebral speci-
mens (four respiratory and one tissue biopsy from lum-
bar vertebrae). In eight patients (16%) the diagnosis
could not be verified by culture.
Drug susceptibility testing for first line drugs was per-
formed for all 41 culture positive cases. Two isolates
were resistant to isoniazid (4%) and one isolate (2%) had
resistance to both rifampicin and isoniazid, thus multi-
drug resistance. No other polyresistance or extensively
drug resistant isolates was identified.
Treatment and outcome
All patients with fully susceptible isolates were treated
with rifampicin (10 mg/kg, max 600 mg), isoniazid
(5 mg/kg, max 300 mg), ethambutol (20 mg/kg, max
Table 2 Cerebrospinal fluid results in 42 patients
Variable Normal range Danes (n = 10) Immigrants (n = 32)
WCC × 106/L, median (range) 0-4 217 (48-590) 104 (1-2970)
CSF lymphocytes, median (range) 70 (3-98) 76 (4-99)
CSF protein g/L, median (range) 0.2-0.5 0.91 (0.15-3.38) 1.65 (0.1-11.7)
CSF glucose mmol/L, median (range) 2.2-3.9 2.1 (0.7-3.9) 2.2 (0.7-8.7)
CSF:blood glucose ratio, median (range)* 0.33-0.66 0.30 (0.10-0.49) 0.31 (0.09-0.71)
Positive smear (%) 0 4 (13)
Positive NAA (%)** 2 (33) 13 (43)
Negative NAA (%)** 4 (67) 17 (57)
Positive mycobacterial culture (%) 7 (70) 24 (75)
WCC = white cell count; CSF = cerebrospinal fluid; NAA = nucleic acid amplification.
*Data from 7 Danes and 19 immigrants.
**Data from 6 Danes and 30 immigrants.
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1200 mg), and pyrazinamide (30 mg/kg, max 2000 mg)
in the first 2 months of the intensive phase of treatment
followed by rifampicin and isoniazid in the continuation
phase of 7- 10 months, except one department where all
patients (n = 25) in this latter phase were treated for a
minimum of 4 months.
Rifabutin was replaced with rifampicin in one HIV
positive patient because a protease inhibitor was part of
the anti-retroviral treatment. Rifampicin was discontin-
ued in one patient due to persistent thrombocytopenia;
isoniazid was discontinued in one patient due to hepato-
toxicity. Two patients did not receive ethambutol as
they had received a kidney transplant. In these cases
either ofloxacin or moxifloxacin were included in
the treatment. Fluoroquinolones and amikacin were
included in the treatment of the patient with multi-drug
resistant TB. Treatment was then given for 24 months.
Corticosteroids were used in all but six patients, of
whom three died before treatment was initiated. Predni-
solone was generally used at an initial dose of 1 mg/kg
with a gradual reduction over 4-6 weeks. There were
12 paediatric patients and all but two received predniso-
lone; one died before TBM was diagnosed.
Neurosurgical intervention in terms of shunting was
performed in four patients with altered cerebral condition
and severe hydrocephalus identified on MR or CT scans.
The delay in initiation of treatment post-admittance
ranged from 0 to 52 days with the highest median of
7 days found in the Danish patient group.
All patients, except two, who were transferred to their
home country, completed the treatment. 16 patients
(33%) had full recovery and 23 (48%) patients had
sequelae. A total of nine patients (19%) died; the age
range was 4-71 years (median 45 years).
Three patients died after several months’ treatment due
to severe neurological sequelae. The remaining six patients
died within one month of admittance; three of these
patients never received any treatment. The cause of death
in the six patients was severe hydrocephalus and infarcts.
Discussion
Extrapulmonary TB accounts for 1/3 of all TB notifica-
tions in Denmark. In 2008, 60% of notified cases were
of other ethnic background than Danish [2]. TBM
remains a rare manifestation of extrapulmonary TB in
Denmark with a consistent incidence of five to six new
cases per year during the past ten years. Almost 80% of
our study population consists of immigrants from coun-
tries of high tuberculosis endemicity. This resembles a
significant increase from the figure of 26% reported in a
Danish study from the 1970s-1980s [6] and also marks
a slight increase from the most recent Danish study
where this figure was 65% [7]. The predominance of
immigrants cannot be linked to health disparity, since
the Danish health system has free and equal access for
all citizens. Another important characteristic of our
patient population is the high prevalence of underlying
immunosuppressive disease; a total of 64% are found in
this study, compared to recent figures of 25% - 35%
[6,7]. 10% of the patients were HIV positive, but it is
worrying that HIV serostatus was not available in 42%.
Since active TB is more common in people infected
with HIV [8], it must be stressed that HIV testing
should always be performed in conjunction with diag-
nosing TBM.
The clinical presentation of TBM is vague with non-
specific symptoms that are hard to distinguish from
other types of bacterial meningitis. It is noted that less
than half our patients had the typical sign of meningeal
stiffness. A long history of illness (over 5-6 days) has
previously been shown to be a clinical variable highly
predictive of TBM [9,10]; we have similar findings with
a median of 10 and 14 days respectively in our two
patient populations.
Biochemical CSF analysis revealed that the majority of
patients (66%) had the characteristic findings of pleocyto-
sis with lymphocyte predominance. Also, protein levels
were, as would be expected, elevated in the majority of
patients as well. Previous studies from Iran, India and
Vietnam have found the percentage of CSF lymphocytes
to be one of the strongest diagnostic variables predictive
of TBM, especially when the total WCC is less than 1000
× 103/ml [11,12]. Only one of our patients had a WCC
above 1000 × 103/ml.
Direct microscopy of CSF for acid-fast bacilli was
positive in only 9.5% of the specimens. This low sensi-
tivity is unfortunate, as this is the simplest diagnostic
tool available and can also be used easily in a low-
resource setting. Other series have found varying sensi-
tivities of a direct smear and figures as high as 58% have
previously been reported [13]. NAA tests have been
shown to be more sensitive and specific than micro-
scopy in diagnosing pulmonary TB [14], but their per-
formance in extrapulmonary specimens, such as CSF,
have been disappointing [15]. In this study the reported
42% sensitivity of NAA is considerably low, but still bet-
ter than the sensitivity of smears. This shows that
Table 3 Neuroradiological findings of 22 patients where
both MR & CT was performed
Danes (n = 7) Immigrants (n = 15)
Finding CT (%) MR (%) CT (%) MR (%)
Basal enhancement 0 6 (86) 2 (13) 10 (67)
Tuberculoma 1 (14) 1 (14) 4 (27) 2 (13)
Hydrocephalus 2 (29) 1 (14) 3 (20) 2 (13)
Fresh cerebral infarct 2 (29) 3 (43) 3 (20) 2 (13)
No pathology 3 (43) 0 6 (40) 2 (13)
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diagnosing TBM in a setting of high resourcefulness
remains challenging.
The culture of CSF samples was positive for M. tuber-
culosis in 74%; this figure is higher than the 55%
reported in two previous Danish studies [6,7]. Culture
remains an essential, but time consuming, tool in diag-
nosing TBM; we report a median of 20 days for bacter-
ial growth to be confirmed. Culture can verify the TBM
diagnosis but cannot be relied on in the initial, critical
diagnostic phase. Culture is however still of importance,
especially for identifying resistant isolates.
The most common findings on neuroradiological
images were basal meningeal enhancement and tubercu-
lomas. As seen clearly in especially the Danish group of
patients, MR scans proved more sensitive for identifying
meningeal enhancement than CT scans (86% vs. 0%).
Tuberculomas were more commonly found in the immi-
grant group. Cranial CT scans seem to be just as sensitive
as MR scans in identifying hydrocephalus, infarcts and
tuberculomas. A recent study found that MR is superior
to CT in identifying basal meningeal enhancement as
well as infarcts; hydrocephalus was in the same study
detected equally by MR and CT scans [16]. In conclusion,
MR scans should be considered as the primary choice for
neuroradiological imaging in the initial diagnostic phase
in a high-resource setting. A total of 46% of our patients
also had pulmonary TB and this emphasises the impor-
tance of chest X-rays and microbiological analyses on
respiratory specimens in the diagnostic process.
The treatment regimes described in this study are not
homogenous. Standard anti-tuberculous drugs were
used at all centres, but the total length of treatment var-
ied from 6-12 months. National guidelines suggest treat-
ment duration of 6 months, except in severe cases,
where 9-12 months treatment regimens are applied, as
also recommended by WHO [17]. This is in contrast to
the recommendations applied in the United Kingdom
and the United States, where all TBM patients are trea-
ted for 9-12 months [18,19]. A high proportion of the
patients were treated with adjuvant prednisolone treat-
ment; this is a well-established component of TBM
treatment and has been shown to significantly reduce
mortality rates [20].
The mortality rate was 19%. The cause of death was
hydrocephalus and/or brain damage in all patients. Simi-
lar studies from other developed nations such as the
United States and Australia have reported mortality
rates of 41% [21] and 7% [22], respectively. From coun-
tries of endemic TB as well as high HIV prevalence,
mortality rates have been significantly higher: from
South Africa 69% [23] and from Vietnam 67% [24]. The
proportion of patients with various neurological seque-
lae in our study is high at 50%, consistent with previous
reports [7].
Conclusions
TBM remains a serious disease even in a setting of low
TB incidence such as Denmark. The disease primarily
affects immigrants from regions of high TB endemicity
and has a high mortality rate and a high rate of sequelae
among survivors. The diagnosis of TBM remains diffi-
cult, even in a high-resource setting, as the currently
available diagnostic tools lack sensitivity. Although TBM
only affects a handful of people each year in Denmark,
the clinician must be prepared to treat empirically if the
suspicion of TBM has arisen.
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